tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

EFXEquifax

Industrials · Credit Bureaus · NYSE

Equifax Inc. is a global data, analytics and technology company. 10-K, Item 1

Employees
15,000
Headquarters
Atlanta, GA
CEO
Mark W. Begor
Next results
around Feb 3, 2027
Compare with peers → Embed

What the 10-K filed 2026-02-19 says about risks that are not on the face of the balance sheet, from the notes to the financial statements, Legal Proceedings and the MD&A (and, for big customers and key suppliers, Business and Risk Factors). Tickdelta picks sentences with specifics (amounts, accruals, covenant ratios) and quotes them as filed. New marks a sentence with nothing like it in the 10-K filed 2025-02-20.

Big customers

Customers the company names as a large share of revenue or receivables (it must name any worth 10% of revenue).

No specific sentence about this in the 10-K.

Key suppliers

Parts or manufacturing that depend on one or a few suppliers.

No specific sentence about this in the 10-K.

Lawsuits and legal claims

5 new

Pending cases, settlements and what the company has set aside for them.

New “plan costs, as well as higher litigation expense and an accrual for a settlement associated with the resolution of four related class action lawsuits.”

Read it in the 10-K ↗

New “The increase in 2025 as compared to 2024 is primarily due to higher people costs which was primarily due to higher incentive plan costs, as well as higher litigation expense, an accrual for a settlement associated with the resolution of four related class action lawsuits and increased depreciation and amortization of capitalized internal-use software costs.”

Read it in the 10-K ↗

New “In January 2026, Equifax and the plaintiffs’ attorneys who filed the lawsuits reached an agreement in principle to settle the claims at issue on a nationwide and class-wide basis.”

Read it in the 10-K ↗

New “The parties have filed a notice of settlement with one federal court and expect to provide the same notice in other pending lawsuits.”

Read it in the 10-K ↗

New “If the final terms of a settlement agreement cannot be agreed upon, or if the settlement is not ultimately approved by the court, Equifax believes it has valid defenses to each of these actions and will continue to defend against them.”

Read it in the 10-K ↗

Guarantees and indemnities

Promises to pay someone else's debts or losses if they cannot.

“The maximum potential future payments we could be required to make under the guarantees is not material at December 31, 2025.”

Read it in the 10-K ↗

“Our investments related to these VIEs totaled $0.3 million at both December 31, 2025 and 2024, representing our maximum exposure to loss, with the exception of the guarantees referenced in Note 6.”

Read it in the 10-K ↗

Debt covenants

Conditions in loan agreements that, if broken, can make debt due early.

“We must comply with various non-financial covenants, including certain limitations on mortgages, liens and sale-leaseback transactions, as well as mergers and sales of substantially all of our assets.”

Read it in the 10-K ↗

“As of December 31, 2025, we were in compliance with all of our debt covenants.”

Read it in the 10-K ↗

“Under the Revolver, the Company must comply with various financial and non-financial covenants.”

Read it in the 10-K ↗

“Compliance with this financial covenant is tested quarterly.”

Read it in the 10-K ↗

“As of December 31, 2025, we were in compliance with our covenants under the Revolver.”

Read it in the 10-K ↗

Commitments off the balance sheet

Contracts the company must pay for later: purchase obligations, take-or-pay deals.

No specific sentence about this in the 10-K.

Sentences are chosen by their words, not read by AI, so some can be off topic. Always check the filing. Open the 10-K ↗

Work on EFX in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/EFX/export.csv") into a cell.